Health Economics›Non-small cell lung cancer›Maintenance after definitive therapy for inoperable disease

Maintenance after definitive therapy for inoperable disease

Non-small cell lung cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Osimertinib monotherapy Variant #01	EGFR	R 77 777	28d	39.1 mo	—	43	R 3 344 409 PFS proxy	1
Durvalumab monotherapy Variant #01	—	R 61 460	14d	14.0 mo	47.5 mo	31	R 1 905 273 PFS proxy	2
Placebo Partial	—	—	—	2.6 mo	11.5 mo	—	—	14
Placebo Partial	EGFR	—	—	2.6 mo	11.5 mo	—	—	14
BCG vaccine monotherapy Variant #01 Partial	—	—	30d	—	~38.6 mo	—	—	1
Sugemalimab monotherapy Variant #01 Partial	—	—	21d	9.0 mo	—	14	—	1

6 of 6 regimens shown